A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure
Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Jan Philipp Bewersdorf, Rory Michael Shallis, Elad Sharon, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan F. Madanat, Joshua F. Zeidner, Jessica K. Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai A. Podoltsev, Stephanie Halene, Richard F. Little, Richard Piekarz, Steven D. Gore, Tae Kon Kim, Amer M. Zeidan
Institutions: Memorial Sloan Kettering Cancer Center, Yale University, Yale Cancer Center, National Cancer Institute, The University of Kansas Cancer Center, The University of Texas Southwestern Medical Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Chicago, Dartmouth–Hitchcock Medical Center, University of Utah, Huntsman Cancer Institute, National Institutes of Health, Vanderbilt University Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310103284